AmerisourceBergen Corp. (NYSE:ABC) EVP John G. Chou sold 6,974 shares of AmerisourceBergen stock in a transaction on Monday, October 15th. The stock was sold at an average price of $88.07, for a total transaction of $614,200.18. Following the sale, the executive vice president now owns 56,125 shares in the company, valued at $4,942,928.75. The sale was disclosed in a document filed with the SEC, which is available through this link.
NYSE ABC opened at $93.76 on Thursday. The company has a current ratio of 0.94, a quick ratio of 0.51 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $19.95 billion, a price-to-earnings ratio of 15.95, a price-to-earnings-growth ratio of 1.44 and a beta of 1.02. AmerisourceBergen Corp. has a one year low of $71.90 and a one year high of $106.27.
AmerisourceBergen (NYSE:ABC) last posted its quarterly earnings data on Thursday, August 2nd. The company reported $1.54 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.08. The company had revenue of $43.14 billion for the quarter, compared to analyst estimates of $43.05 billion. AmerisourceBergen had a net margin of 0.69% and a return on equity of 48.65%. AmerisourceBergen’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.43 earnings per share. Equities analysts anticipate that AmerisourceBergen Corp. will post 6.48 earnings per share for the current year.
Several brokerages recently commented on ABC. ValuEngine upgraded shares of AmerisourceBergen from a “sell” rating to a “hold” rating in a research note on Wednesday, August 15th. Robert W. Baird reiterated a “neutral” rating and set a $94.00 price target on shares of AmerisourceBergen in a research note on Friday, July 20th. Mizuho reiterated a “neutral” rating on shares of AmerisourceBergen in a research note on Wednesday, September 19th. Morgan Stanley cut their price target on shares of AmerisourceBergen from $97.00 to $88.00 and set an “equal weight” rating on the stock in a research note on Tuesday, July 3rd. Finally, Zacks Investment Research lowered shares of AmerisourceBergen from a “hold” rating to a “sell” rating in a research note on Wednesday, October 3rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. AmerisourceBergen currently has an average rating of “Hold” and an average target price of $101.80.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Further Reading: Do Tariffs Work?
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.